Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
31 December 2018 | Story Xolisa Mnukwa | Photo Supplied
Johan Kotze
Johan Kotze, captain of the Shimlas, was announced as the club’s best senior player for 2018.

The 2018 rugby year proved to be a reconstructive one for the Shimlas after they parted ways with several members of their team in 2017. A fresh and inexperienced Shimla team, branded as the youngest squad ever, came two log points short of reaching the semi-finals of the Varsity Cup. Ten of the players in the squad were still U19 last year.  

 

Several victories

 

After winning three of their first four encounters, including two away fixtures, the Shimlas were set for a spot in the semi-finals, which could possibly have been a home game. The three victories were against the defending champions Tuks by 19-17, 44-24 against Wits, and a 32-27 win over Ikeys.

The Shimlas played a total of 17 matches in 2018, claiming victory in 12. They finished fourth at the University Sport South Africa (USSA) tournament and won the Mangaung Metro league.

 

Players of the Year

Johan Kotze, Shimla captain and prop, was titled ‘Senior Player of the Year’. In the same breath, Lubabalo Dobela and Rewan Kruger, who both played for the Junior Springboks, were jointly selected as the ‘Junior Players of the Year’.

Vishuis was named the country’s best hostel rugby team for the third consecutive year. They defeated Patria of the North-West University in the finals by 55-29.

The UFS U20 team won all four of their matches in the group stage of the Young Guns competition before they lost to Tuks in the semi-final. The Kovsie Sevens team won the bowl competition at the USSA tournament and at the Varsity Sevens they ended in 6th position.

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.
Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept